169 related articles for article (PubMed ID: 33372604)
1. Intrahepatic cholangiocarcinoma induced M2-polarized tumor-associated macrophages facilitate tumor growth and invasiveness.
Yuan H; Lin Z; Liu Y; Jiang Y; Liu K; Tu M; Yao N; Qu C; Hong J
Cancer Cell Int; 2020 Dec; 20(1):586. PubMed ID: 33372604
[TBL] [Abstract][Full Text] [Related]
2. M2-polarized tumor-associated macrophages promote epithelial-mesenchymal transition via activation of the AKT3/PRAS40 signaling pathway in intrahepatic cholangiocarcinoma.
Sun D; Luo T; Dong P; Zhang N; Chen J; Zhang S; Dong L; Janssen HLA; Zhang S
J Cell Biochem; 2020 Apr; 121(4):2828-2838. PubMed ID: 31692069
[TBL] [Abstract][Full Text] [Related]
3. Tumor-associated neutrophils and macrophages interaction contributes to intrahepatic cholangiocarcinoma progression by activating STAT3.
Zhou Z; Wang P; Sun R; Li J; Hu Z; Xin H; Luo C; Zhou J; Fan J; Zhou S
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33692217
[TBL] [Abstract][Full Text] [Related]
4. Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma.
Hasita H; Komohara Y; Okabe H; Masuda T; Ohnishi K; Lei XF; Beppu T; Baba H; Takeya M
Cancer Sci; 2010 Aug; 101(8):1913-9. PubMed ID: 20545696
[TBL] [Abstract][Full Text] [Related]
5. M2-polarized tumor-associated macrophages promoted epithelial-mesenchymal transition in pancreatic cancer cells, partially through TLR4/IL-10 signaling pathway.
Liu CY; Xu JY; Shi XY; Huang W; Ruan TY; Xie P; Ding JL
Lab Invest; 2013 Jul; 93(7):844-54. PubMed ID: 23752129
[TBL] [Abstract][Full Text] [Related]
6. M2-polarized tumor-associated macrophages facilitated migration and epithelial-mesenchymal transition of HCC cells via the TLR4/STAT3 signaling pathway.
Yao RR; Li JH; Zhang R; Chen RX; Wang YH
World J Surg Oncol; 2018 Jan; 16(1):9. PubMed ID: 29338742
[TBL] [Abstract][Full Text] [Related]
7. IRG1 restrains M2 macrophage polarization and suppresses intrahepatic cholangiocarcinoma progression via the CCL18/STAT3 pathway.
Zhou M; Yu H; Bai M; Lu S; Wang C; Ke S; Huang J; Li Z; Xu Y; Yin B; Li X; Feng Z; Fu Y; Jiang H; Ma Y
Cancer Sci; 2024 Mar; 115(3):777-790. PubMed ID: 38228495
[TBL] [Abstract][Full Text] [Related]
8. ALOX5 acts as a key role in regulating the immune microenvironment in intrahepatic cholangiocarcinoma, recruiting tumor-associated macrophages through PI3K pathway.
Chen J; Tang Y; Qin D; Yu X; Tong H; Tang C; Tang Z
J Transl Med; 2023 Dec; 21(1):923. PubMed ID: 38124204
[TBL] [Abstract][Full Text] [Related]
9. M2 macrophage inhibits the antitumor effects of Lenvatinib on intrahepatic cholangiocarcinoma.
Yang L; Han P; Cui T; Miao Y; Zhao T; Cui Z; Chen Y; Chi H; Zhang J; Zhang Y
Front Immunol; 2023; 14():1251648. PubMed ID: 37809069
[TBL] [Abstract][Full Text] [Related]
10. (-)-Guaiol inhibit epithelial-mesenchymal transition in lung cancer via suppressing M2 macrophages mediated STAT3 signaling pathway.
Cao Y; Wu Y; Tu H; Gu Z; Yu F; Huang W; Shen L; Wang L; Li Y
Heliyon; 2023 Sep; 9(9):e19817. PubMed ID: 37809930
[TBL] [Abstract][Full Text] [Related]
11. LncRNA-CCAT1 Promotes Migration, Invasion, and EMT in Intrahepatic Cholangiocarcinoma Through Suppressing miR-152.
Zhang S; Xiao J; Chai Y; Du YY; Liu Z; Huang K; Zhou X; Zhou W
Dig Dis Sci; 2017 Nov; 62(11):3050-3058. PubMed ID: 28921383
[TBL] [Abstract][Full Text] [Related]
12. FXR Acts as a Metastasis Suppressor in Intrahepatic Cholangiocarcinoma by Inhibiting IL-6-Induced Epithelial-Mesenchymal Transition.
Lv B; Ma L; Tang W; Huang P; Yang B; Wang L; Chen S; Gao Q; Zhang S; Xia J
Cell Physiol Biochem; 2018; 48(1):158-172. PubMed ID: 30001540
[TBL] [Abstract][Full Text] [Related]
13. TLR2 promotes human intrahepatic cholangiocarcinoma cell migration and invasion by modulating NF-κB pathway-mediated inflammatory responses.
Liu B; Yan S; Jia Y; Ma J; Wu S; Xu Y; Shang M; Mao A
FEBS J; 2016 Oct; 283(20):3839-3850. PubMed ID: 27616304
[TBL] [Abstract][Full Text] [Related]
14. IL-33/ST2 Signaling and its Correlation with Macrophage Heterogeneity and Clinicopathologic Features in Human Intrahepatic Cholangiocarcinoma.
Yasen A; Yang Z; Feng J; Liang R; Dai T; Li K; Cai Y; Wang G
Curr Cancer Drug Targets; 2024 Jan; ():. PubMed ID: 38299398
[TBL] [Abstract][Full Text] [Related]
15. Antitumor and antimetastatic actions of xanthoangelol and 4-hydroxyderricin isolated from Angelica keiskei roots through the inhibited activation and differentiation of M2 macrophages.
Sumiyoshi M; Taniguchi M; Baba K; Kimura Y
Phytomedicine; 2015 Jul; 22(7-8):759-67. PubMed ID: 26141763
[TBL] [Abstract][Full Text] [Related]
16. Tumor-associated macrophages promote cancer stem cell-like properties via transforming growth factor-beta1-induced epithelial-mesenchymal transition in hepatocellular carcinoma.
Fan QM; Jing YY; Yu GF; Kou XR; Ye F; Gao L; Li R; Zhao QD; Yang Y; Lu ZH; Wei LX
Cancer Lett; 2014 Oct; 352(2):160-8. PubMed ID: 24892648
[TBL] [Abstract][Full Text] [Related]
17. Co-culture of ovarian cancer stem-like cells with macrophages induced SKOV3 cells stemness via IL-8/STAT3 signaling.
Ning Y; Cui Y; Li X; Cao X; Chen A; Xu C; Cao J; Luo X
Biomed Pharmacother; 2018 Jul; 103():262-271. PubMed ID: 29656182
[TBL] [Abstract][Full Text] [Related]
18. Tumor associated macrophages provide the survival resistance of tumor cells to hypoxic microenvironmental condition through IL-6 receptor-mediated signals.
Jeong SK; Kim JS; Lee CG; Park YS; Kim SD; Yoon SO; Han DH; Lee KY; Jeong MH; Jo WS
Immunobiology; 2017 Jan; 222(1):55-65. PubMed ID: 26705936
[TBL] [Abstract][Full Text] [Related]
19. Quantitative changes in tumor-associated M2 macrophages characterize cholangiocarcinoma and their association with metastasis.
Thanee M; Loilome W; Techasen A; Namwat N; Boonmars T; Pairojkul C; Yongvanit P
Asian Pac J Cancer Prev; 2015; 16(7):3043-50. PubMed ID: 25854403
[TBL] [Abstract][Full Text] [Related]
20. Crosstalk between cancer cells and tumor associated macrophages is required for mesenchymal circulating tumor cell-mediated colorectal cancer metastasis.
Wei C; Yang C; Wang S; Shi D; Zhang C; Lin X; Liu Q; Dou R; Xiong B
Mol Cancer; 2019 Mar; 18(1):64. PubMed ID: 30927925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
